Fig. 1

MIR31HG is highly expressed in thyroid cancer. A Immunohistochemical staining of Ki67 in primary tumor samples and matched normal thyroid samples from the same patients (n = 5). B Relative MIR31HG expression as measured by qRT-PCR in primary tumor samples and matched normal thyroid samples from the same patients (n = 29), normalized to β-actin expression. C Kaplan-Meier survival curves of these patients with high MIR31HG expression (n = 13) and low MIR31HG expression (n = 16). The p value was from a long-rank test. D Relative MIR31HG expression in HTH83, SW579, TPC-1, and Nthy-ori 3–1 cells by qRT-PCR, normalized to β-actin expression. E and F The subcellular localization of MIR31HG in SW579 and TPC-1 cells was determined by subcellular fractionation analysis. U6 and GAPDH served as controls. **P < 0.01, ****P < 0.0001